Feb. 20, 2026—Arlington Scientific has completed its acquisition of Awareness Technology’s EIA/ELISA product line. The assays will be part of the SeraQuest line and aim to strengthen ASI’s FDA-registered serology platform, which includes agglutination, latex, and ELISA methodologies.
“As part of ASI’s growth strategy, we focus on expanding in ways that reinforce our core strengths in manufacturing, quality, and regulatory execution,” Park Roney, president and CEO of ASI, said in a press release. “Bringing these established ELISA assays into ASI allows us to broaden our diagnostics offering and add the consistency and reliability our laboratory partners expect.”